Processa Pharmaceuticals, Inc. (PCSA) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and non-oncology drug candidates. The company operates as a single segment focused on research and development (R&D) and has no product revenue. As of the filing date, the company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,436,573) | $(3,384,703) | $(10,204,896) | $(9,121,410) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(1.03) | $(0.41) | $(3.13) |
| Operating Expenses (Total) | $3,488,843 | $3,424,853 | $10,286,616 | $9,316,475 |
| Cash and Cash Equivalents (End of Period) | $6,308,420 | $2,891,464 | $6,308,420 | $2,891,464 |
| Net Cash Used in Operating Activities (YTD) | $(8,484,617) | $(8,997,321) | $(8,484,617) | $(8,997,321) |
| Net Cash Provided by Financing Activities (YTD) | $13,601,712 | $7,185,832 | $13,601,712 | $7,185,832 |
| Accumulated Deficit | $(97,424,095) | $(84,490,491) | $(97,424,095) | $(84,490,491) |
Liquidity Note: The company holds $350,000 in USD-backed stablecoins classified as cash equivalents as of September 30, 2025. Subsequent to the period end, an additional $500,000 was transferred to digital asset wallets.
Material Changes vs. Prior Period
- Capital Raising: The company significantly increased its cash position through multiple equity financings in 2025. Net proceeds totaled approximately $10.6 million from public offerings in January and June, plus $2.2 million from private placements and ATM sales in August. This contrasts with $7.2 million in financing proceeds during the same period in 2024.
- Expense Trends:
- Research & Development (R&D): Decreased by $626,000 in Q3 2025 compared to Q3 2024, primarily due to lower preclinical and clinical trial costs for the NGC-Cap Phase 2 trial compared to the initiation costs incurred in 2024.
- General & Administrative (G&A): Increased by $690,000 in Q3 2025. Drivers included higher executive salaries ($214,000), investment management fees related to digital assets ($150,000), and increased stock-based compensation ($139,000).
- Share Count: Weighted average shares outstanding increased significantly from ~3.3 million in Q3 2024 to ~47.5 million in Q3 2025 due to equity issuances, resulting in a lower loss per share despite a similar absolute net loss.
Guidance, Outlook, and Risks
- Going Concern: Management states that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the filing date without additional funding. Current cash reserves are projected to satisfy capital needs only into the first quarter of 2026.
- Cryptocurrency Strategy: On August 7, 2025, the company announced a corporate cryptocurrency treasury strategy to acquire and hold digital assets (stablecoins and others) to diversify capital and potentially generate yield. This introduces new risks regarding volatility, cybersecurity, and regulatory classification of assets.
- Clinical Pipeline:
- NGC-Cap: Phase 2 trial for advanced/metastatic breast cancer is ongoing with active patient enrollment.
- PCS499: Re-evaluating potential for primary glomerular diseases (PGDs); plans to meet with the FDA in Q4 2025.
- PCS12852: Entered a binding term sheet with Intact Therapeutics for an exclusive license option. Potential upfront payment of $2.5 million and equity interest in Intact, subject to due diligence.
- Nasdaq Compliance: The company received a deficiency letter regarding the $1.00 minimum bid price requirement. A reverse stock split was approved by shareholders in September 2025 to regain compliance. Nasdaq granted an extension until February 2, 2026.
- Legal Proceedings: Ongoing litigation includes a dispute with Elion regarding a license agreement termination and a lawsuit by former investors alleging fraud (partially dismissed, discovery ongoing).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.3 million cash balance against projected burn rates to confirm the "first quarter of 2026" liquidity timeline.
- Digital Asset Exposure: Review the specific terms of the cryptocurrency treasury strategy, custodial arrangements, and the volatility risk associated with the $850,000 (post-period) digital asset holdings.
- License Agreement Status: Monitor the due diligence timeline with Intact Therapeutics for the PCS12852 license, as the $2.5 million payment is contingent on closing.
- Nasdaq Listing: Confirm the successful implementation of the reverse stock split and subsequent compliance with the $1.00 minimum bid price to avoid delisting.
- Dilution Impact: Assess the impact of the significant increase in share count (from ~3.7M to ~52.9M outstanding) on future equity value and potential further dilution required for funding.